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Abstract. Two clinical studies were conducted to investigate the efficacy and safety of epoetin beta 
in 26 anemic predialysis patients. Epoetin beta was administered subeutaneously either daily or 
thrice weekly. Mean duration of treatment was 211 days (interquartile range: 105 to 350 days). 
Results: Renal anemia could be corrected and the regular transfusion need could be eliminated in all 
patients. There was no difference in the dose requirement per week between daily and thrice weekly 
administration of epoetin beta. Regarding the entire study population, there was no acceleration of 
the progression of renal failure during epoetin beta treatment nor were there any notable changes in 
laboratory values other than retention values. Epoetin beta was sale and well tolerated; the most 
important adverse event was the development or aggravation of hypertension.
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Introduction eration of chronic renal failure. The initial data from
experiments appei to irm
Since the mid-eighties, recombinant human erythro- [Myers et al. 1975, Gretz et al. 1987].
In however, a possible influence ofpoietin (rhEPO) has been used successfully to correct 
renal anemia and to eliminate the chronic need for trans­
fusions in patients with end-stage renal failure (ESRF) blood pressure of the animals treated with rhEPO was 
[Bommer et al. 1988, Eschbach et al. 1991, Samtleben et distinctly higher than in the controls (Garcia et al. 1988|. 
al. 1991, Scigalla et al. 1990, Canadian Erythropoietin These animal experiments were therefore repeated with
Study Group . As renal anemia is monitoring of blood pressure.
frequently very pronounced even in the compensated antihypertensive treatment prevented an acceleration of 
stage of chronic renal failure, attempts were made to use the progression of renal failure in the animals treated 
rhEPO to correct renal anemia in predialysis patients with rhEPO [Ruedin et al. 1991}.
[Frenken et al. , Lim et al. 1990, Eschbach et al. rhe results of the pilot clinical studies in predialysis
19891. Irrespective of uremia, an increase in packed cell patients with normal blood pressure (with or without
volume, and thus blood viscosity, will cause a greater rise antihypertensive 
of efferent than of afferent vascular resistance in the PCV to values
that an increase in
Í
change in kidney function (Lini et al.
•  i ' l l1 icant
al. »1 ne and Frenken I
Two multicenter studies were conducted with simi-
caliber and have a greater length than the afferent arterio­
les. The result is a rise in glomerular intracapillary pres­
sure, independnt of the patient’s systemic blood pressure, lar designs except for the frequency of s 
This is reflected in the clinical findings that glomerular epoetin beta (a recombinant human ei 
filtration fraction rises when polycythemia is induced and aims of both studies were: 
decreases after phlebotomy [Koene and Frenken 1992).
There were concerns that the rise in glomerular trans- 
membrane pressure would result in destruction of renal 
structure, glomerulosclerosis and ultimately in the accel-
to estimate the epoetin beta dose required to reach
and to maintain the target PCV,
to investigate
s .c .  £
of daily or thrice weekly,
beta on renal anemia
cell count,
Sim m
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in terms of changes in PCV, red 
transfusion need and iron metablism 
to evaluate the effect of epoetin beta on 
sion of renal failure, and
to determine the clinical tolerability of epoetin beta 
in uremic predialysis patients with anemia.
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Methods run-in phase, was at least 1%  and if no blood transfusions
were given in the preceding 4 weeks.
Patients and study design On achieving the target PCV (end of correction
phase), the last required epoetin beta dose was reduced 
Since the efficacy of s.c. rhEPO in uremic dialysis by 500 IU in patients with daily administration and by 
patients had already been demonstrated, double-blind, 1000 IU in patients receiving epoetin beta three times a 
placebo-controlled studies were not considered ethically week. In patients who reached the target PCV with 500 
justifiable. Therefore both studies were conducted with- or 1000 IU, the epoetin beta dose was halved to 250 or
out a control group. 500 IU. During the maintenance phase the individual 
epoetin beta doses were adjusted according to the course
of PCV. The patients reported to the investigators every 4
Inclusion criteria
Adult patients with renal anemia
(PCV < 30 vol %) and stable chronic renal failure. A Determined variables
prerequisite for the enrollment of the patients in the 
study was the availability of 8 to 10 serum creatinine During the studies, the following variables were de-
values in the patients’ medical records over the last 1 to termined: body weight, blood pressure, hemoglobin, PCV,
4 years. erythrocytes, reticulocytes, platelets, leucocytes and dif­
ferential blood count; creatinine, urea, potassium, sodium,
Primary exclusion criteria
phosphate, calcium, alkaline phosphatase, transaminases, 
total protein, albumin, prothrombin time, PTT, iron, ferri-
Epilepsy, thrombocytosis, poorly controlled hyper­
tension, iron, vitamin B I2 or folic acid deficiency, malig-
tin, transferrin, EPO serum levels and anti-EPO antibodies.
nant tumor, acute or chronic infections.
Dose regimen
The two studies were analyzed together, because the 
study design and the study variables were identical. For
primary variables, study analysis was stratified by ad-
The patients in one study received epoetin beta ministration frequency.
daily at first and the patients in the other study received The PCV increase per week for the first six weeks
epoetin beta three times a week. The reason for the daily of the correction phase (without a dose increase) and for
administration in the first trial was the observation from a the total correction phase (primary variable) were calcu-
pilot study by Granolleras et al. [1991] that the dose lated individually as the difference between the final
could be reduced by daily rhEPO administration. How- value o f the respective phase minus the baseline value,
ever, this hypothesis was not confirmed [Bommer et al. divided by the individual number of weeks.
1991], and therefore an amendment was made to the The primary variable of the maintenance phase was
study protocol, allowing the investigators to choose the individual mean epoetin beta dose per week to main-
admini strati on three times per week. tain the corrected PCV. The individual maintenance dose
The initial dosage o f epoetin beta s.c. was set as fol-
lows:
< 75  kg body weight: 3 X 1Ö00IU per week or 
7 X 500 IU per week
mithe mean dose in 
phase excluding the first 90 days.
The slope of the reciprocal of serum creatinine 
versus time was determined by linear regression methods
> 75 kg body weight: 3 X  2000 IU per week or for each patient before and after the start of epoetin beta
7 X  1000 IU per week treatment. Two-sided Wilcoxon signed rank tests on the
the effect
of epoetin beta treatment on progression of renal failure
During the correction phase, the patients reported to differences of the slopes were used to ant 
the investigators every two weeks.
If the PCV increase was < 3% after 6 weeks, the in all patients and in the various subgroups, 
dose was to be increased by 500 IU epoetin beta in pa­
tients with daily administration and by 1000 IU epoetin 
beta in patients with administration three times a week.
This was to be repeated in 4-week intervals until the tar­
get PCV of 33-37% was attained. The individual target 
PCV was reached if the individual increase of PCV, com-
Results
275 uremic predialysis patients with distinct hypo- 
generative anemia were enrolled (242 patients in Ger-
pared to the mean value of the three PCV values in the many, 33 patients in the Netherlands).
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Nine patients dropped out of the study during the 105 to 350 days); 129 patients were treated for more than 
run-in phase (need for dialysis [n = 3], personal reasons half a year and 54 patients for more than one year.
[n 6]). 266 patients were treated with epoetin beta and The renal anemia was corrected by epoetin beta in
analyzed for safety. Patients were excluded from the effi- both frequency groups. During the first 6 weeks the 
cacy analysis if the mean PCV value in the run-in phase increase in PCV was 0.403% (median) with treatment
was above 30% without blood transfusions (n 15), if three times a week and 0.648% (median) with treatment
they were treated with epoetin beta for less than four seven times a week. When calculated for the whole eor- 
weeks (n = 18), or if the initial administration frequency rection phase, the increases in PCV were 0.519% 
deviated from the study plan, (n = 8 patients treated an) and 0.515% 
neither 3 times nor 7 times a week). Therefore 225 pa­
tients fullfilled the criteria for the efficacy analysis. The 25.6% to 33.7% 
underlying diseases, basic demographic data 
tory parameters are summarized in Table 1.
During the correction phase, the PCV rose from
1
in the
a week and from 25.6 to 33.0%
treated three times
m group
treated seven times a week. The PCV remained stable
the do s a ire wasduring the maintenance phase
Efficacy The median epoetin beta dose required to maintain
the target PCV was 55 U/kg body weight per week (three 
The median duration of therapy in the 225 patients times a week) and 61 U/kg body weight per week (seven 
evaluated for efficacy was 211 days (interquartile range: times a week). The median maintenance dose for the total
Table 1 Underlying diseases, basic demographic data and laboratory parameters for uremic predialysis patients treated with rhEPO (median, inter­
quartile ranges)
Efficacy population
Sex
Male
Treatment
3 X/week 7X/week total
n = 17 n — 67 n =  84
Female n =31 n = 110 n =  141
Age (years) 54 56 56
(43-68) (46-65) (46-66)
PCV (%) 25,6 25.6 25,6
(23.7-27.0) (23.7-27.7) (23.7-27.4)
Mb (g/dl) 8.6 8.6 8.6
(8.0-9.0) (7.8-9.1) (7.8-9.1)
Corrected reticulocytes (Ïit-) 6.8 7.3 7.2
(4.1 -9.9) (5.1-10.2) (5.0- 10.2)
« « m im m i— — m ra i li...... in n i, i w *m i iitiw  rvi i W| m1 Tummn inm rnynuraujW ’.ECjntiwi i  k iim ininn ........  r t MMf* nnÉi»mr>n»M liu t i.... . imuwiiMiiinniiuniiiiiimu'm limut; iinnutii|in i'i
3 * I t  I*
t& m wiftn
total
Underlying disease li % n % n %
Chronic glomerulonephritis 7 14.6 28 15.8 35 15.6
Diabetic nephropathy 2 4.2 36 20.3 38 16.9
Hereditary nephropathy 7 14.6 9 5.1 16 7.1
Interstitial nephritis 10 20.8 19 10.7 20 12.9
Nephrosclerosis 1 2.1 8 4.5 9 4.0
Pyelonephritis 3 6.3 15 8.5 18 8.0
Renal failure due to chronic graft rejection 5 10.4 18 10.2 23 10.2
Unknown and other 13 27.1 44 24.9 57 25.3
Total 48 100 177 100 100
M*S
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population was 58 U/kg body weight per week (inter- of stimulation of erythropoiesis; the median serum ferri-
quartile range: 42 to 81 U/kg body weight per week).
Transfusion requirement
During the last month before enrollment into the 
study, 8.4% of the patients received at least one blood
tin fell from 143.0 fxg/ml to 94.0 |xg/ml and transferrin 
saturation fell from 20.7 to 17.5%. During the mainten­
ance phase body iron stores recovered; the serum ferritin 
level increased from 79 |xg/ml to 129.5 fxg/ml, and trans­
ferrin saturation also showed a tendency towards baseline.
transfusion. This transfusion need was nearly eliminated Progression o f  renal failure
(< 1% per month) after one month of treatment. Only 
individual patients required transfusions on single occa­
sions for acute bleeding.
The course of 1 /serum creatinine versus time was 
analyzed to assess the impact of epoetin beta treatment 
on the progression of renal failure. With regard to the 
total study population, no difference could be detected 
when comparing the slope of 1/serum creatinine before 
and after epoetin beta treatment (Table 2), showing that 
Of the total of 266 patients 131 received iron substi- there was no change in the rate of progression of renal 
tution at the start of the study. Iron substitution was failure during epoetin beta therapy compared with that 
initiated in 40 of 135 patients not originally receiving before.
Iron stores
iron medication, i.v. in six of them. During the correction Analysis of patients stratified by underlying disease
phase there was a decrease in body iron stores as a result (Table 3, Figure 1) showed no relevant differences in the
Table 2 Regression of 1/creatinine (X 10-4 dl/mg) slope before and under treatment with rhEPO in anemic, uremic predialysis patients (n = 253)
Median Minimum 1 st quartile 3rd quartile Maximum
Before -1.828 -58.310 -3.652 - 1 .0 0 1 +17.761
Under — 1.660 -37.447 -4.626 -0.353 +25.189
A slope +0.303*) -31.376 -1.858 + 1.838 +83.499
Acceleration of progression (A slope <0) n = 115 (45.5%) 
Deceleration of progression (A slope >0) n = 138 (54,5%) 
*) Wilcoxon Signed Rank Test p = 0,8537
Table 3 Differences in slopes of 1/crealinine (X 10'4 
patients
g) after start minus before start of epoetin beta treatment in anemic, uremic predialysis
A positive slope means deceleration of the progression of renal disease 
*) Wilcoxon Signed Rank Test
N Median I. Quartile 3. Quartile p-value*
Total 253 0.303 -1.858 1.838 0.854
Chronic glomerulonephritis 40 0.096 -1.612 1.802 0.732
Diabetic nephropathy 42 0.846 —2,166 3.274 0.398
Hereditary nephropathy 20 0.519 -0.706 2.526 0.216
Interstitial nephritis 32 0.559 -3.146 1.491 0.546
Nephrosclerosis 10 -2 .1 9 1 -4.125 0.807 0.160
Pyelonephritis 21 0.957 -1 .0 7 1 2.726 0.511
Renal failure due to chronic graft rejection 25 0.584 -3.857 1.838 0.824
Unknown and other 63 -0.241 -1.580 1.503 0.389
Baseline creatinine <4m g% 51 0.701 -2.875 2.151 0.775
> 4 - < 6 m g % 88 0.387 -2.655 2.102 0.941
>  6 mg% 114 0.085 -1.420 1.673 0.981
Duration of treatment >  180 d 130 0.752 -0.405 1.858 0.0001
Duration of treatment >360 d 58 0.798 -0.151 1.838 0.0001
Epoetin betel in anemic p r e d ia l  y six patients
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Table 4 Adverse events classified as being possibly related to epoetin ences in the required weekly dosages were observed be-
beta therapy
Adverse event Number of patients Number o f  AEs
Hypertension 18 20
Headache 5 6
Terminal renal failure 3
F
3
Shunt thrombosis n
j  * 
h !..
V
»1
ih
Deep-vein thrombosis 1 1
Menorrhagia n i
Stenocardia 3
Flu-like-syndrome 1 2
Deterioration in retention values T i
Pruritus 1 1
Vertigo, fatigue - )4 * * T
tween the administration scheme of three times a week 
and daily administration of epoetin beta. The mainten­
ance dosage was 55 IU/kg body weight per week and 
61 IU/kg body weight per week, respectively. These 
findings correspond with published data [Eschbach et al. 
1989, Scigalla et al. 1990, Graf et al. 1992].
Investigations o f  renal function under epoetin beta
'rupy m pre 'SIS nits
of ives of is was to investi­
ci correction of renal anemia in patients
with uremia not yet 
eration in the
I dialysis, leads to an accel-
of renal failure. The linear 
regression of the reciprocal values of serum creatinine 
levels before and after epoetin beta therapy was calcu- 
patients showed a hypertensive reaction. During the lated for each patient. The slope of the regression line 
maintenance phase, one patient became hypertensive was taken as a measure of the progression of renal lail- 
without requiring AHT; AHT was initiated in four pa- ure. This approach is based on the results of various 
tients and in 35 patients the dosage was increased, i. e, studies, which showed that the reciprocal of the serum
26% of patients showed a hypertensive reaction. creatinine levels declines linearly with time. The decline
Except for the laboratory parameters that reflect the is approximately proportional to the reduction of crea- 
progression of renal failure, none of the safety laboratory tinine clearance [Walser 1990, Gretz et al. 1983 ). How- 
parameters monitored showed any notable changes ever, when using this method one must take into account
during epoetin beta.
No anti-EPO antibodies were detected.
Discussion
Efficacy o f  subcutaneous epoetin beta in uremic 
predialys is patien ts
the fact that the serum creatinine level is influenced by 
many factors, e. g. functional and drug-induced tubular 
secretion of creatinine and changes in creatinine metabo­
lism. Nevertheless, observation of the slope of the regres­
sion line is the only practical way of obtaining an indica­
tion of the progression of renal failure in the long-term.
Under epoetin beta therapy the slope of 1/creatinine
pro­
gression of renal failure compared to pretreatment time; 
In the two studies reported, therapy was started with however, this difference is not statistically significant, 
low dosages of epoetin beta (approx. 60 IU/kg/week), The result of our studies agree with data from other stu- 
The basic reasons for the low dosages were:
-  There is no medical need to rapidly correct c
renal anemia; by a moderate correction the 
can adapt to the new PCV more readily and with 
fewer or even no side effects.
If therapy is started with high dosages of epoetin 
beta the rate at which the PCV rises can be in­
creased, but the efficacy calculated in relation to the 
cumulative dose of epoetin beta (= cumulative
dies. In all these studies, some of which were conducted
over one year í 
serum creatinine
more,
was
ne in : rec
to be constant, i. e.
• renal failure was not affected by rhEPO
therapy [Fi 
et al.
et al. Lini et al. 1990, Eschbach
4c 1 , Graf et al.
Stone et al. , Teehan et al. 1991, Abraham et al.
The above results are also confirmed by other kid-
erythropoietin dose until the target PCV is reached) ney function studies [ Koene and Frenken 1992, Abraham
is reduced. et al. 1990]. These study groups determined or calculated
The dose regimen used in the studies is sufficient to the glomerular filtration rate, renal plasma flow, extra­
reach a satisfactory target PCV within a reasonable time. renal plasma flow and the filtration fraction before and 
Therefore the following dosage recommendations can be during rhEPO therapy. They found no changes within 8 
made: Start with 3 X 20 IU/kg body weight and week to 18 weeks of rhEPO therapy. It is worth emphasizing 
s.c. in the correction phase. Thereafter, the dosage may that the blood pressure of these patients remained normal 
be increased every 4 weeks by 3 X 20 IU/kg body weight with or without antihypertensive therapy, 
and week if the increase in PCV is not adequate (< 0.5% Up to now only one study has been published show- 
per week). In these anemic predialysis patients, no differ- ing a deterioration of kidney function [Onoyama et al.
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1989]. In this study, kidney function was determined by an overestimation of the epoetin beta effect. The main
means oi inulin and PAH clearance before and after reason for this is that the incidence 
4 weeks of rhEPO therapy. After an increase in PCV usually rises as renal failure progresses, mainly due to an 
from 21 to 27%, a slight decrease in the extrarenal plas- increase in hyperhydration.
ma flow and a slight increase in the glomerular filtration It is important to state
pressure rose from 171/73 mmHg to 190/105 mmHg.
To summarize, the clinical results agree with the
results from animal al.
Gretz et al. 1987, Garcia et al. 1988, Ruedin et al. 
In both animal experiments and clinical trials, i
only rarely. This
renal failure [Raine
the i
rate was found. The filtration fraction was thus signifi- reactions were controlled 
cantly increased. However, it must be stressed that blood therapy and that serious
is also important mainly because 
in other studies that systemic
•ession of
renal failure was
systemic blood pressure rose significantly. The increase Conclusions 
in PCV alone did not lead to a deterioration in kidney
The results of the two 
In general, no difference could be detected when summarized as follows:
comparing the progression of renal failure before treat­
ment with that during epoetin beta treatment, nor was 
there an influence of the baseline state of renal failure.
Considering the groups with specific underlying 
renal diseases separately, a tendency towards acceleration 
of the progression of renal failure cannot be ruled out 
entirely in patients with nephrosclerosis.
Adverse events during epoetin beta in uremic 
p red ia lys is p  a tien ts
The evaluation of the in
population of 266 patients treated with epoetin beta in the 
two clinical trials was difficult because the patients were
and theenrolled in studies without a placebo c 
uremic predialysis
Renal anemia in uremic predialysis patients can be
corr and the need for regular
eliminated with epoetin beta.
In general, there was no acceleration of the progres­
sion of renal failure during epoetin beta therapy.
The most important adverse event during epoetin 
beta therapy is the development or aggravation of 
hypertension. Hypertensive patients should only be 
treated with epoetin beta if their blood pressure is
sis uremic patients no clinically relevant
•e to be expected in 1 Pr i  t > 1
risks of treatment can be identified and 
managed, the risk-benefit ratio of epoetin beta for 
renal anemia in predialysis patients is favourable.
with an impaired function and structure of organs
In order to obtain an v i u v v n
the individual clinical course of the patients and thus all REFERENCES 
adverse events were analyzed in consultation with the
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ical hit 
In dialysis patients incidence of thromboem
sis, is not
than without.
s are of special interest in a 
therapy which leads to an increase in PCV. In the two 
studies available there was only one case of a deep vein 
thrombosis and two cases of shunt thrombosis, which
to epo-I t \  1*
etin beta therapy.
beta therapy a 
tients in the correction phase and 
reaching the maintenance phase had a
of 24% of pa- 
of the patients
» m u r .
on blood pressure are s
the effects of epoetin 
in patients with E
, Opsahl JA, Rachael KM, A,vin^er R, Halxtmsm Cfi
1990 Renal function during erythropoietin therapy for anemia 
in predialysis chronic renal failure patients. Am j Nephrol 10:
128
Hammer J, Barth H-P, Zeier M, Maiulelbautn A, Hammer 0 , Rit.*
Reicltel 11, Novaek R 1991 Efficacy comparison of intravenous 
and subcutaneous recombinant human erythropoietin administra­
tion in hemodialysis patients. In: Garland 11 J, Moran J, Samtle* 
hen VK Scigalla P, Wieczorek I, (cds) Contrih Nephrol. Karger, 
Basel, vol 88, p 136 
Hammer J, Kugel M, Schoeppe VK Brunkhorst R, Samt leben W Brain-
siepe P, Scigalla P 1988 Dose-related effects of 
human erythropoietin on erythropoiesis. In: Koch KM, Kuehn K,
Nonnast-Datuel H, Seigalla P  (eds) Contrih Nephrol.
Basel, vol 66, p 85
I*
alysis patients.
dence of s is
4  t
double-blind study of recombinant human
(r-HU-EPO) in chronic sis. Kidney Int .f.-t
208 K o c h , K o e n e , M e s s in g e r  e t a i
Canadian Erythropoietin Study Group: Association between recom- Lim KS', Fangman J, Flanigan MJ, DeGowin RL, Abels RT  1990 Effect
binant human erythropoietin and quality of life and exercise 
capacity of patients receiving hemodialysis. Br Med J 300: 
573
Eschbach JW, Kelly MR> Haley NR, Abels RIt Adamson J 1989 Treat­
ment of the anemia of progressive renal failure with recombinant 
human erythropoietin, N Engl J Med 321: 158
Eschbach JW Eg rie JC, Downing MR% Browne JK, Adamson JW 1991
The safety of Epoietin-Alpha: Results of clinical trials in the 
United States. In: Gurland HJt Moran ./, Samtleben W, Scigalla
of recombinant human erythropoietin on renal function in 
humans. Kidney lnt 37: 131 
Myers BD, Deen W, Robertson CR, Brenner BM 1975 Dynamics of
glomerular ultrafiltrtion in the rat. VIII. Effects of hematocrit. 
Circ Res 36: 425
Onoyama K , Kumagai H, Takeda K} Shimamasu K, Fujishima M  1989
Effects of human recombinant erythropoietin on anaemia,
i
systemic haemodynamics and renal function in predialysis renal 
failure patients. Nephrol Dial Transplant 4: 966
P, Wieczorek L (eds) Contrib Nephrol. Karger, Basel, vol 88, Raine AE 1988 Hypertension, blood viscosity and cardiovascular mor-
p 72
Frenken LAM, Verberckmoes R, Michlelsen P, Koene RAP 1989 Effi-
in renal failure: Implications of therapy.
Lancet I; 97
cacy and tolerance of treatment with recombinant human Ruedin P, Lemoine R, Boillie M, Leslie M, KaitferA  1991 Prevention of
erythropoietin in chronic renal failure (pre-dialysis) patients. accelerated progression of renal failure induced by recombinant
Nephrol Dial Transplant 4: 782 human erythropoietin in the rat remnant kidney. (Abstract)
Garcia DL, Anderson S, Rennke HG, Brenner BM 1988 Anemia les- Nephrol Dial Transpl 6: 828
sens and its prevention with recombinant erythropoietin worsens Samtlehen W, E lm er B, Lutz-Knochenhamr 1, Hagmann Ch, Scigalla
glomerular injury and hypertension in rats with reduced renal 
mass. Proc Natl Acad Sei 85: 6142 
Graf H, Barnas U, Stifter S et al. 1992 Effectiveness and safety of
recombinant human erythropoietin in predialysis patients.
Nephron 61: 399
Granolleras C, Branger B, Shaldon S, Nonnast-Daniel B, Koch KM,
Pollok M, Baldamus CA 1991 Subcutaneous erythropoietin: A 
comparison of daily and thrice weekly administration. In: Gur-
P, Gurland HJ 1991 Side effects during recombinant human 
erythropoietin therapy in 2000 ESRD patients. In: Gurland HJ, 
Moran J, Samtleben W, Scigalla P, Wieczorek L (eds) Contrib 
Nephrol. Karger, Basel, vol 88, p 107
Scigalla P, Messinger D, Wieczorek L 1990 Reasons for differences
in dose requirements of recombinant human erythropoietin in 
haemodialysis patients. In: Tanaka H  (ed) Contrib Nephrol. 
Karger, Basel, vol 82, p 55
land HJ, Moran J, Samtleben VU Scigalla P, Wieczorek L (eds) Scigalla P, Wieczorek L, Bicker U 1990 Treatment of renal anemia
Contrib Nephrol. Karger, Basel, vol 88, p 144
Gretz N, Manz F, Strauch M 1983 Predictability of the progression of
chronic renal failure. Kidney lnt 24, Suppl 15: 2
with recombinant human erythropoietin: European experience. 
In: Garnick MB (ed) Erythropoietin in clinical applications: an 
international perspective. Marcel Dekker, New York, p 141
Gretz N, Lasserre JJ, Meisinger E, Strauch M, Waldherr R, Kraft K, Stone WJ, Gräber SE, Krantz SB, Dessypris EM, O ’Neil VL, Olsen N,
Weidler A 1987 Potential side-effects of erythropoietin. Lancet 
I; 46
Koene RAP, Frenken 1AM  1990 Does treatment of predialysis patients
Pincus TP 1988 Treatment of the anemia of predialysis 
patients with recombinant human erythropoietin: A randomized, 
placebo-controlled trial. Am J Med Sciences 296; 171
with recombinant human erythropoietin compromise renai fune- Teehan B, Krantz SB, Stane WA, Graber S, Abels R et al. 1991 Doublé
tion? In: Schaefer RM, Heidland A, Hoerl WH (eds) Contrib 
Nephrol. Karger, Basel, vol 87, p 105 
Koene RAP, Frenken LAM 1992 Role of rHuEPO in treatment of ure-
blind, placebo-controlled study of the therapeutic use of recom­
binant human erythropoietin for anemia associated with chronic 
renal failure in predialysis patients. Am J Kidn Dis 18: 50
mic anemia prior to end-stage renal disease. Kidn lnt 42, Suppl Walser M 1990 Progression of chronic renal failure in man. Kidney lnt
38: 142 37:1195
